The FDA approved several therapies in oncology in the month of March 2025. These drugs included treatments for ...

After a year of stripping back its head count and pipeline, Carisma Therapeutics is now cutting down to the bone and laying ...

BeiGene, Ltd. , a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European ...

On the commercial front, Akeso's adjustments in drug pricing and optimization of its commercial systems led to new drug sales revenue surpassing RMB 2 billion in 2024, a 25% year-on-year increase. The ...

There were a number of notable developments for patients with kidney cancer at the symposium, Dr. Emre Yekedüz explained.

The FDA has approved Tevimbra with chemotherapy for the first-line treatment of unresectable or metastatic ESCC whose tumors express PD-L1.

Given the patient’s favorable initial tumor response and strong request, immunotherapy was cautiously reinstated using tislelizumab after thorough clinical evaluation. Following four cycles of ...

Harry H. Yoon, MD, MHS, discusses tislelizumab and platinum-containing chemotherapy in unresectable or metastatic esophageal ...

The expansion arm will assess the safety, optimal dosing, and early anti-tumor activity of Decoy20 in combination with tislelizumab. Initial participants will receive a week of Decoy20 monotherapy ...

The company recently said it will apply for regulatory approval in Korea and the US in the second quarter to test a combination of its cancer drug candidate, BAL0891, with immunotherapy drug Tevimbra ...

Indaptus Therapeutics, Inc. (NASDAQ:INDP) announced it advanced to a new expansion arm of its Phase 1b/2 clinical trial of Decoy20. The expansion will evaluate the combination of Decoy20 with BeiGene ...

This expansion will evaluate the combination of Decoy20 with BeiGene’s PD-1 checkpoint inhibitor, tislelizumab, with a focus on safety, dose optimization, and early signs of anti-tumor activity.